<DOC>
	<DOCNO>NCT00453609</DOCNO>
	<brief_summary>The overall goal project improve treatment alcohol dependence patient serious mental illness ( SMI ) . SMI study define patient follow diagnosis : schizophrenia , schizoaffective disorder , bipolar type I type II disorder . Alcohol substance use disorder ( SUDs ) common among individual SMI . SUD comorbidity associate many adverse consequence . However , date , report address efficacy pharmacological treatment SUDs population . Naltrexone pharmacotherapy effective treatment alcohol dependence , systematically apply care patient SMI . The primary aim study determine feasibility long-acting injectable naltrexone administration clinical trial patient SMI also diagnosis alcohol dependence . Secondary aim include provide preliminary assessment tolerability safety long-acting injectable naltrexone patient SMI also diagnosis alcohol dependence . An additional aim provide preliminary assessment efficacy long-acting injectable naltrexone reduce alcohol use baseline level .</brief_summary>
	<brief_title>Injectable Naltrexone Treatment Alcohol Dependence Serious Mental Illness ( SMI )</brief_title>
	<detailed_description>The propose project 1-year pilot program research , examine feasibility new , intramuscular ( IM ) long-acting form naltrexone . The long-acting form naltrexone may improve medication adherence , show critical successful naltrexone treatment alcohol dependence . The study 16-week , randomize , prospective , open-label trial , include 12-week course monthly naltrexone injection . A follow-up interview conduct 4 week discontinuation medication . Thirty subject recruit . Voucher-based incentive provide subject ensure attendance medication administration . Weekly motivational counseling session conduct focus improve motivation stop alcohol use . Study outcomes consist self-report biological measure alcohol use ; measure psychiatric symptom severity neurocognitive functioning ; genetic test examine functional polymorphism ( Asn40Asp ) differences subject ' Î¼-opioid receptor ( OPRM1 ) , may predict response naltrexone treatment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1 . Males female , age 18 69 , DSMIV diagnosis Schizophrenia , Schizoaffective Disorder , Bipolar Type I Type II Disorder . 2 . DSMIV diagnosis Alcohol Dependence last 12 month . 3 . Level Drinking : 1 . At least four day drink 30 day prior consent and/or screen period OR 2 . For prospective subject currently inpatient residential facility recently discharge within 30 day prior consent : At least 4 day drink period time immediately prior inpatient admission and/or postdischarge . 4 . Currently prescribe antipsychotic medication , mood stabilizer , antidepressant . 5 . One negative urine screen opiates prior start medication selfreport opioid use least 1 week prior start medication . 6 . Currently involved outpatient psychiatric treatment one study site ( Hutchings Psychiatric Center , SUNY Upstate Adult Psychiatric Clinic , St. Joseph 's Hospital , VA Medical Center ) another location community . 1 . Inability give adequate inform consent ; 2 . Currently take disulfiram ( Antabuse ) , naltrexone , acamprosate ( Campral ) ; 3 . Current DSMIV diagnosis Opioid Dependence ( criterion meet last month ) ; 4 . Current regular use prescribe opioid analgesic , methadone , morphine , codeine , meperidine , opioids . If subject report take prescribed opioid analgesic occasionally , study physician nurse practitioner contact prescribe physician regard safety study participation possibility use alternative . The principal investigator make final determination obtain primary physician 's recommendation regard criterion . 5 . Current daily use nonprescribed opioids . 6 . Currently take ibuprofen potentially hepatotoxic medication amount and/or frequency judge Principal Investigator pose clinically significant add risk hepatic injury ; 7 . Female patient childbearing potential sexually active , sterile , deny use birth control ; 8 . Female patient pregnant nursing ; 9 . Significant unstable medical problem , include significant unstable psychiatric disorder . The study physician conduct medical history physical exam exclude clinically unstable individual ; 10 . AST ( aspartate aminotransferase test ) level : If AST great 3x upper limit normal ; 11 . Subjects attend require screening appointment . Subsequent exclusion study reason relate nonattendance base judgment principal investigator ; 12 . In need acute medical detoxification alcohol judgment study physician base result score 12 Clinical Institute Withdrawal Assessment Alcohol Scale Based DSMIIIR ( CIWAAD ) information obtain ; 13 . Scheduled surgery within 3 month intake ; 14 . Subjects pending legal proceeding whose outcome may lead incarceration within 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Bipolar Disorders</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective Disorders</keyword>
	<keyword>Alcohol Dependence</keyword>
	<keyword>Long-lasting injectable naltrexone</keyword>
</DOC>